Incyte Corp. (0J9P)
London Exchange · UK · prices in USD · close of 19 Oct 2026
Key indicators
| Last close | USD 113.73 |
|---|---|
| 52-week range | 83.00 – 134.99 |
| Return, 1 month / 3 months | −10.0% / −3.1% |
| Return, 1 year / 3 years | +33.3% / +89.6% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 41 |
| Volatility (1 year) | 33.0% |
| Worst drawdown (1 year) | -18.3% |
| Average daily value traded | 0.23M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Incyte is a biopharmaceutical company based in the United States that discovers, develops and commercialises medicines for cancer and inflammatory conditions. Its products include treatments for rare blood cancers and a topical medicine for skin conditions, sold mainly to specialist physicians and hospitals. The company also runs a portfolio of clinical programmes in oncology and immune disorders, and earns royalty revenue from partners who market some of its medicines outside its home market.
The shares are listed on the London Exchange in UK under the code 0J9P, and the price on this page is in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Incyte Corp. (0J9P) trades on the London Exchange in UK. It last closed at USD 113.73 on 19 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 1,061 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 33.3% and over the last three months it fell 3.1%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 5.8% | ||
| From 52-week high | -12.6% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.1% | ||
| 6-month return | 16.4% | ||
| 12-month return, skipping the last month | 48.0% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 33.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -18.3% | ||
| Liquidity | 38 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.23M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.1% |
|---|---|
| 1 month | −10.0% |
| 3 months | −3.1% |
| 6 months | +16.4% |
| 1 year | +33.3% |
| 3 years | +89.6% |
| 5 years | – |
Signals
| 50-day / 200-day average | 121.93 / 107.50 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 5.05 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.